Back to Search
Start Over
A Novel Bispecific Antibody Targeting PD-L1 and VEGF With Combined Anti-Tumor Activities.
- Source :
-
Frontiers in immunology [Front Immunol] 2021 Dec 02; Vol. 12, pp. 778978. Date of Electronic Publication: 2021 Dec 02 (Print Publication: 2021). - Publication Year :
- 2021
-
Abstract
- Therapeutic monoclonal antibodies (mAbs) blocking immune checkpoints have been mainly used as monotherapy. Recently, combination therapy targeting multiple immune checkpoints has recently been explored to increase anti-cancer efficacy. Particularly, a single molecule targeting more than one checkpoints has been investigated. As dual blocking of PD-1/PD-L1 and VEGF/VEGFR has demonstrated synergism in anti-tumor activities, we developed a novel bispecific antibody, termed HB0025, which is formed via fusing the domain 2 of vascular endothelial growth factor receptor 1 (VEGFR1D2) and anti-PD-L1 mAb by using mAb-Trap technology. HB0025 almost completely retains the binding affinities and the biological activities in-vitro when compared with the parent anti-PD-L1 mAb or VEGFR1D2 fusion protein. Preclinical data demonstrated that HB0025 was more effective in inhibiting cancer growth than anti PD-L1 mAb or VEGFR1D2 fusion protein. Thus, our bispecific antibody may bring about greater clinical benefits and broader indications.<br />Competing Interests: Authors XCu, HJ, SC, SX, XL, WX, XCh, YF, XW, HY, YW, YZ XZ were employed by company Huabo Biopharma and authors LZ and XZ were employed by Huaota Biopharma. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2021 Cui, Jia, Xin, Zhang, Chen, Xia, Li, Xu, Chen, Feng, Wei, Yu, Wang, Zhan, Zhu and Zhang.)
- Subjects :
- Animals
Antibodies, Bispecific genetics
Antibodies, Bispecific therapeutic use
Cell Line, Tumor
Human Umbilical Vein Endothelial Cells
Humans
Male
Mice
Neoplasms pathology
Protein Domains genetics
Recombinant Fusion Proteins genetics
Recombinant Fusion Proteins therapeutic use
Vascular Endothelial Growth Factor Receptor-2 genetics
Xenograft Model Antitumor Assays
Antibodies, Bispecific pharmacology
B7-H1 Antigen antagonists & inhibitors
Neoplasms drug therapy
Recombinant Fusion Proteins pharmacology
Vascular Endothelial Growth Factor A antagonists & inhibitors
Subjects
Details
- Language :
- English
- ISSN :
- 1664-3224
- Volume :
- 12
- Database :
- MEDLINE
- Journal :
- Frontiers in immunology
- Publication Type :
- Academic Journal
- Accession number :
- 34925354
- Full Text :
- https://doi.org/10.3389/fimmu.2021.778978